On one wall of endocrinologist Kevan Herold’s office hangs artwork by a girl who joined one of his type 1 diabetes trials when she was 11 years old. The girl was diagnosed with stage 2 of the disease, ...

Learn about the KCET 2026 Eligibility Criteria, including academic qualification, domicile eligibility, nationality, ...

Interim efficacy analysis highlights potential value of combination therapy of ENV-105 and apalutamide following positive safety data Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopha ...

Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and ...

Although teplizumab doesn’t work for everyone and how much it delays progression varies, it has inspired new directions in ...

In exchange for the exclusive license to casdatifan, Taiho will make an option exercise payment, as well as additional payments upon achievement of clinical, regulatory and commercialization ...

MICVO received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of adult patients with R/M HNSCC whose disease has progressed following treatment with platinum-based ...

Abstract Number: 4351248 Title: A Phase 1b, Double-Blind, Placebo-Controlled Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Nondialysis-Dependent CKD and Anemia Date / Time: ...

Henna artist Risa Raghunanan-Mohammed is still on a high from her win at the Body Art Battle competition, which was part of ...

Drug candidates spanning oncology, neurology, rare diseases and more are approaching critical development as the calendar turns to 2026.